Previous 10 | Next 10 |
Precigen Announces Proposed Public Offering of Common Stock PR Newswire GERMANTOWN, Md. , Jan. 21, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced it has commenced an underwritten public offering of shares of its common stock. In ad...
The following slide deck was published by Precigen, Inc. in conjunction with this event. For further details see: Precigen (PGEN) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow
Precigen (PGEN) announces that preliminary data from Phase I study of PRGN-2009 AdenoVerse immunotherapy in HPV-associated cancers show increase in immune response upon repeated administration of PRGN-2009 monotherapy.The Phase I study is evaluating safety and response of PRGN-2009 alone...
Precigen Provides Pipeline Updates at the 39th Annual J.P. Morgan Healthcare Conference - Company announced its vision to transform the personalized cell therapy landscape using non-viral, antigen-specific UltraCAR-T® library approach - - Preliminary data from Phase I s...
SAN DIEGO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in NASDAQ: PGEN shares. Investors, who purchased shares of Precigen, Inc. (NASDAQ: PGEN) in June 2017 or earlier and continue to hold any of those NAS...
2020 was a year of immense adversity and contrast, as stocks bounced back sharply from a pandemic-induced bear market. Biotechs play a pivotal role in managing down the pandemic as vaccine production ramps higher. January to provide further insights on multiple additional vaccine tria...
Precigen to Present at the 39th Annual J.P. Morgan Healthcare Conference - Management will also participate in a panel discussion at the H.C. Wainwright BioConnect 2021 Conference - PR Newswire GERMANTOWN, Md. , Jan. 6, 2021 /PRNewswire/ -- Precigen, In...
The FDA has cleared Precigen's (PGEN) Investigational New Drug ((IND)) application to initiate a Phase I clinical trial of PRGN-2012, an investigational off-the-shelf AdenoVerse immunotherapy in adult patients with recurrent respiratory papillomatosis ((RRP)), a rare and sometimes fatal neopl...
Precigen Announces Clearance of IND to Initiate Phase I Study of PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP) - First off-the-shelf AdenoVerse immunotherapy targeting infectious disease to enter the clinic - - RRP is ...
Precigen Provides Latest Clinical Developments at Virtual R&D Update Event GERMANTOWN, Md. , Dec. 15, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve ...
News, Short Squeeze, Breakout and More Instantly...
2024-06-03 14:30:04 ET Stifel Nicolaus analyst issues MARKET OUTPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Market Outperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst co...
2024-06-03 14:30:03 ET JMP Securities analyst issues UNDERPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Underperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst consensus : B...
Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response PR Newswire – Phase 1/2 pivotal study met the primary safety and efficacy endpoints ...